Nilotinib-Induced Dystonia and Cognitive Deficits in a Neurologically Normal Patient with Chronic Myeloid Leukemia
Nilotinib is a tyrosine kinase inhibitor used to treat patients with chronic myeloid leukemia (CML).This agent is also being studied in neurodegenerative disorders including Parkinson disease.Studies have shown that nilotinib may decrease the accumulation of parkin substrates and decrease Bike Parts - Bearings the loss of dopaminergic cells.The use